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Capsular Gene Typing of Streptococcus agalactiae Compared to
Serotyping by Latex Agglutination
Kaihu Yao,a,b Knud Poulsen,a Domenico Maione,c C. Daniela Rinaudo,c Lucilla Baldassarri,d John L. Telford,c
Uffe B. Skov Sørensen, Members of the DEVANI Study Group,a Mogens Kiliana
Department of Biomedicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmarka; Beijing Pediatric Research Institute, Beijing Children’s Hospital affiliated to
Capital Medical University, Beijing, People’s Republic of Chinab; Novartis Vaccines and Diagnostics, Siena, Italyc; Dipartimento di Malattie Infettive, Parassitarie ed
Immunomediate, Instituto Superiore di Sanita, Rome, Italyd
We evaluated three different PCR-based capsular gene typing methods applied to 312 human and bovine Streptococcus agalac-
tiae (group B Streptococcus [GBS]) isolates and compared the results to serotyping results obtained by latex agglutination.
Among 281 human isolates 27% could not be typed by latex agglutination. All 312 isolates except 5 could be typed by the three
PCRmethods combined. Two of these methods were multiplex assays. Among the isolates that were typeable by both latex ag-
glutination and capsular gene typing, 94% showed agreement between the twomethods. However, each of the PCRmethods
showed limitations. One of the methods did not include all 10 recognized serotypes, one misidentified eight isolates of serotypes
Ib and IV as serotype Ia, and one did not distinguish between serotypes VII and IX. For five isolates that showed aberrant pat-
terns in the capsular gene typing, long-range PCR targeting the cps operon disclosed large insertions or deletions affecting the
cps gene cluster. A sensitive flow cytometric assay based on serotype-specific antibodies applied to 76 selected isolates that were
nontypeable by latex agglutination revealed that approximately one-half of these did express capsular polysaccharide. A proce-
dure for convenient and reliable capsular gene typing to be included in epidemiological and surveillance studies of S. agalactiae
is proposed.
Streptococcus agalactiae (group B Streptococcus [GBS]) emergedas an important human pathogen in the 1960s and has become
the leading cause of neonatal invasive infections (1–3). More re-
cently, S. agalactiaehas also been recognized as a common cause of
infections in immunocompromised patients and in the elderly
(4). In addition, S. agalactiae is a notable cause of contagious mas-
titis in cattle (5). Some evolutionary lineages of the species are
exclusively adapted to either humans or cattle and have spread
globally, whereas others are genetically more diverse and may col-
onize both hosts (6). In addition, S. agalactiae may be isolated
from other species including other mammals, amphibians, and
fish. Subpopulations of S. agalactiae originating from these animal
species may occasionally cause infections in humans (7, 8).
The polysaccharide capsule is a major virulence factor in inva-
sive disease caused by S. agalactiae, enabling the bacterium to
evade host innate defense mechanisms (9). The most commonly
used method for serotyping of S. agalactiae is latex agglutination
based on polyclonal antibodies specific for the 10 recognized cap-
sular polysaccharides, i.e., serotypes Ia, Ib, and II to IX. Serological
methods have limitations, as they may fail to type an isolate due to
lack of or low expression of capsular polysaccharide under the
experimental conditions. Furthermore, these methods are highly
dependent on the quality of the antibodies used and on the expe-
rience of the laboratory (10). Therefore, capsular gene typing is an
attractive alternative. Recently, several methods for typing of S.
agalactiae based on PCR targeting genes in the cps operon were
published. In this study, we compared three different PCR-based
capsular gene typing methods (11–14) with serotyping by latex
agglutination. In addition, the expression of capsular polysaccha-
rides in strains that were nontypeable by latex agglutination was
evaluated by a sensitive flow cytometric analysis (15) using mono-
clonal or polyclonal antibodies specific for the five most common
serotypes.
MATERIALS AND METHODS
S. agalactiae isolates. A total of 312 S. agalactiae isolates were included in
the study. Among these, 281 were vaginorectal isolates obtained from
pregnant women (n 251) and clinical isolates from neonatal infections
(n 30) in Belgium, Bulgaria, the Czech Republic, Denmark, Germany,
Great Britain, Italy, and Spain. These isolates were collected during the
DEVANI project (Design of a Vaccine against Neonatal Infections) sup-
ported by the European Commission Seventh Framework. Among these
DEVANI isolates, 77 were received from other participating laboratories
as being problematic in serotyping by latex agglutination. In addition to
these human isolates, 31 bovine S. agalactiae strains, nontypeable by se-
rological means, were included from our previous global study (6). These
strains were isolated in Australia (n 5), Europe (n 15), and the United
States (n 11).
All included strains were confirmed as S. agalactiae by a positive Remel
Streptex Latex Group B test (Thermo Fisher Scientific), a positive PCR
using primers dltS-F and dltS-R as described previously (14), and a posi-
tive CAMP reaction. Isolates were cultured on blood agar plates at 37°C in
air plus 5% CO2 and in Todd-Hewitt broth (Oxoid).
Serotyping by latex agglutination. The S. agalactiae strains were cul-
tured on blood agar plates. A heavy suspension of the test organism har-
vested from the blood agar plate was prepared in 250 l phosphate-buff-
ered saline (PBS), pH 7.4. For each of the 10 serotypes, a 20-l aliquot of
the bacterial suspension was applied to a Wellcogen disposable reaction
card and mixed with 1l of latex suspension (reagents Ia, Ib, and II to IX;
Strep-B-Latex kit; Statens Serum Institut, Copenhagen, Denmark) as re-
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cently described (10). The reaction card was rotated slowly and observed
for agglutination, and a positive reaction was scored when clear-cut ag-
glutination appeared within 30 s. Notably, false-positive reactions may
occur if the reaction time exceeds 30 s. Serotyping by latex agglutination
and the capsular gene typing described below were performed in the same
laboratory at Aarhus University.
Antibodies.Mouse monoclonal antibodies (MAbs) were generated by
Areta International (Varese, Italy) using standard protocols. Hybridoma
clones were screened by enzyme-linked immunosorbent assay (ELISA).
Positive clones were then tested for binding to the surface of S. agalactiae
by flow cytometry, and the MAbs were purified by protein G affinity
chromatography.
A polyclonal antiserum specific for capsular polysaccharide type II was
produced by immunizing CD1 mice with the purified tetanus toxoid-
conjugated serotype II polysaccharide. Animal treatments were per-
formed in compliance with the Italian laws and approved by the institu-
tional review board (Animal Ethical Committee) of Novartis Vaccines
and Diagnostics, Siena, Italy.
Serotyping by flow cytometry. Fluorescence-activated cell analysis
was performed as described elsewhere (15) by using MAbs specific for S.
agalactiae capsular polysaccharides Ia, Ib, III, and V and a polyclonal
serum specific for the polysaccharide type II (see above). Briefly, mid-
exponential-phase S. agalactiae cells were fixed in 0.08% (wt/vol) paraform-
aldehyde and incubated for 1 h at 37°C. Fixed bacteria were then washed
once with PBS, resuspended in newborn calf serum (Sigma), and incu-
bated for 20 min at 25°C. The cells were then incubated for 1 h at 4°C in the
presence of MAbs in preimmune or immune sera, diluted 1:200 in dilu-
tion buffer (PBS, 20% newborn calf serum, 0.1% bovine serum albumin
[BSA]). Cells were washed in PBS– 0.1% BSA and incubated for a further
1 h at 4°C with a 1:100 dilution of R-phycoerythrin-conjugated F(ab)2
goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc.). After
washing, cells were resuspended in PBS and analyzed with a fluorescence-
activated cell sorting (FACS) CANTO II apparatus (Becton, Dickinson,
Franklin Lakes, NJ) using FlowJo Software (Tree Star, Ashland, OR).
Capsular gene typing.Genomic DNA was prepared using the Nucleo-
Spin Tissue kit (Macherey-Nagel). Approximately 1 ng of DNA was used
in the PCRs with primers as described elsewhere (11–14). For the one-set
multiplex PCR described by Imperi et al. (11), we used the 5 Prime Hot-
Master Mix kit (5 Prime); for the two-set multiplex PCR described by
Poyart et al. (14), we used AmpliTaq Gold with GeneAmp (Roche); and
for the serotype-specific PCRs described by Kong et al. (12, 13), we used
PuReTaq Ready-To-Go PCR beads (GE Healthcare). The amplicons were
analyzed by agarose gel electrophoresis, and the presence of DNA frag-
ments of the same size as in one of the strains with known serotype was
used to establish the capsular gene type. For the multiplex PCR described
by Imperi et al. (11), we used 1.5% and for the other methods 1% agarose
gels (SeaKem ME agarose; Lonza).
Long-range PCR. The primers GBS-cpsA-F, 5=-TGGCTCTATATCA
ACAGTATCAAGATCTGA-3=, and GBS-neuA-R, 5=-CTCAATATCTGC
ATTATTGACAGTTTCTCT-3=, targeting the cpsA gene (the first gene in
the cps operon) and the neuA gene (the last gene in the cps operon),
respectively, were used in long-range PCR with the Advantage Genomic
LA (Clonetech). The samples were amplified by a denaturation step for 2
min at 94°C, followed by 30 cycles of 94°C for 10 s, 55°C for 30 s, and 68°C
for 20 min and a final elongation of 68°C for 10 min.
RESULTS
Serotyping by latex agglutination. The study included 281 hu-
man and 31 bovine isolates of S. agalactiae. Among the human S.
agalactiae strains, latex agglutination assigned 205 to one of the 10
known serotypes, 74 did not react with any of the reagents and
were scored as nontypeable, and 2 showed autoagglutination. Be-
ing selected as previously nonserotypeable, none of the bovine
isolates included were typeable by latex agglutination.
Capsular gene typing.The 312 strains were all examined by the
three capsular gene typing methods as described in Materials and
Methods. Each of the three methods showed limitations. The two-
set multiplex PCR developed by Poyart et al. (14) was published
before the discovery of serotype IX (16), and serotype IX strains
were found to yield a PCR product of the same size as those of
serotype VII strains in this test (Fig. 1). In the one-set multiplex
PCR developed by Imperi et al. (11), the middle band in six and
two strains of serotypes Ib and IV, respectively, was very weak or
not detectable, and therefore, strains of these serotypes may be
incorrectly typed as serotype Ia, which is characterized by the lack
of the middle band (Fig. 2). The serotype-specific PCRs described
by Kong et al. (12, 13), which we used to confirm the results of the
two multiplex PCRs described above, do not include a PCR spe-
cific for serotypes II, VII, or VIII.
By combining all results, 307 strains were unambiguously as-
signed to a capsular gene type, showing full agreement between
the three PCR methods used except for the limitations pointed out
above. Five strains only, four of human and one of bovine origin,
showed an aberrant amplicon pattern or lack of amplicons in at
least one of the PCRs and could not be unambiguously typed. The
sizes of amplicons obtained in the long-range PCR targeting the
cps operon indicated that insertions or deletions (indels) had af-
fected the cps gene cluster in these strains (Fig. 3). Among these
FIG 1 Serotype IX strains are identified as serotype VII in the two-set multi-
plex PCR (14). Lanes 1 to 3, amplicons from the multiplex PCR performed as
described by Imperi et al. (11); lanes 4 to 6, amplicons from the multiplex PCR
2 performed as described by Poyart et al. (14). M, molecular weight marker;
lanes 1 and 4, strain CZ-PW-093 (serotype VII); lanes 2 and 5, strain CZ-PW-
032 (serotype IX); lanes 3 and 6, DE-PW-092 (serotype IX). FIG 2 Examples of weak bands in the multiplex PCR performed as described
by Imperi et al. (11). M, molecular weight marker; lane 1, DE-PW-096 (sero-
type Ib); lane 2, DE-PW-203 (serotype Ib); lane 3, DE-PW-196 (serotype IV);
lane 4, ES-PW-167 (serotype IV); lane 5, DE-PW-091 (serotype Ia). The weak
bands are marked by asterisks.
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five strains, four were nontypeable by latex agglutination, whereas
one was positive for serotype IX (Table 1), which most likely is a
mistake because of the problems with the serotype IX reagent in
the Strep-B-Latex kit (see below).
Of the 204 human strains that were typeable by both latex
agglutination and capsular gene typing, 191 strains (94%) showed
agreement between the two methods (Table 1). The 13 strains that
showed disagreement were assigned to serotypes V, VIII, or IX by
latex agglutination and to Ia, Ib, II, III, IV, or V by molecular
capsular gene typing (Table 1). Among the 31 bovine strains that
were nontypeable by latex agglutination, 4, 3, 16, 2, 4, and 1 strains
were assigned to serotypes Ia, Ib, II, III, IV, and V, respectively, by
the capsular gene typing method. One bovine strain was nontype-
able by all methods. No serotype VIII strain was detected by any of
the PCR methods.
Detection of capsule expression by flow cytometry. As a neg-
ative result with the latex reagents may be due to lack of gene
expression, a sensitive flow cytometric assay was used to test for
lack of versus low expression of capsular polysaccharide in se-
lected strains that were typeable by capsular gene typing only and
not by latex agglutination. Monoclonal antibodies against sero-
type Ia, Ib, III, and V polysaccharides and a polyclonal antibody
against serotype II were available for the analysis, and strains ex-
hibiting other capsular gene types were excluded. Among 50 hu-
man and 26 bovine strains tested, 28 and 11, respectively, could be
typed by flow cytometry, indicating that these strains expressed
amounts of capsular polysaccharide undetectable by the latex ag-
glutination test, as confirmed by the complete agreement of the
reactions with the molecular typing results. The 22 human and 15
bovine strains negative in the flow cytometric assay presumably do
not express capsular polysaccharides. This explanation is sup-
ported by the finding that the five strains that were nontypeable by
gene typing due to disruptive deletions or insertions in the cps
locus were all nontypeable by flow cytometry. Besides, the flow
cytometric analyses confirmed the capsular gene typing for three
strains that showed discrepant results in the latex agglutination
assay.
Capsule gene locus. Long-range PCR on the cps operon was
performed on a selection of 41 strains that could be typed by the
molecular methods and were negative in latex agglutination.
Among these, 33 strains had capsular gene types that were covered
by the antibodies used in the flow cytometric assay, and they were
selected because they were negative in this assay, whereas the re-
maining 8 strains had capsular gene types not covered by the flow
cytometric assay. One human strain showed no amplicon in this
PCR analysis, presumably due to strain variation in the primer-
binding sites. Among the remaining 23 human and 17 bovine S.
agalactiae strains tested, the amplified fragment was of a size com-
patible with an intact cps operon, indicating that the presence of
larger indels in the cps operon was not the molecular mechanism
causing lack of capsule expression.
DISCUSSION
Like current vaccines against Streptococcus pneumoniae and Hae-
mophilus influenzae serotype b, future vaccines against S. agalac-
tiae infections are presumed to include capsular polysaccharides
from the most common types associated with disease. The capsule
is the major known protective antigen, and capsular conjugate
vaccines are in clinical trials (17). Therefore, correct serotyping of
clinical isolates is essential to predict vaccine coverage. Available
methods are based either on agglutination with serotype-specific
FIG 3 Long-range PCR with primers cpsA-F and neuA-R flanking the cps
locus on the five strains that were nontypeable by the molecular capsular gene
typing method. For comparison, three strains that could be typed by both
serology and PCR are included. Lane 1, CZ-PW-123 (serotype Ia); lane 2,
DE-PW-121 (serotype III); lane 3, DE-PW-119 (serotype Ib); lane 4, GB-PW-
013 (nontypeable); lane 5, USS215 (nontypeable, bovine strain); lane 6, IT-
PW-0085 (nontypeable); lane 7, IMMI266 (nontypeable); lane 8, GB-PW-075
(nontypeable); M, molecular weight marker.
TABLE 1 Typing of 281 human GBS isolates by latex agglutination and a combination of PCR methods
Serotype assigned by
latex agglutination
No. of isolates assigned by molecular capsular gene typing to serotype:






V 2 2 30
VII 1
VIII 1
IX 3 1 2 1 1 7 1
NT 22 3 13 18 4 10 1 3
Autoaggregation 2
a NT, nontypeable.
Capsule Typing of GBS
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reagents or on detection of serotype-specific sequences in the cap-
sular polysaccharide biosynthesis gene loci. For strains that were
typeable by both latex agglutination and capsular gene typing, our
study showed a high degree of agreement (94%) between results
obtained by the two methods. However, the results identify a
problem with the serotype V and IX latex reagents (Statens Serum
Institute) used for the agglutination tests (Table 1). Moreover, the
accuracy of the results is highly dependent on experience (10), and
the latex agglutination assay is less sensitive than the flow cytomet-
ric method as demonstrated by our observation that approxi-
mately one-half of the strains scored as nontypeable in this assay
were found to express type-specific polysaccharides when exam-
ined by the flow cytometric method. The exact proportion of un-
selected isolates that would present this problem in clinical micro-
biology is not clear, as the strain collection examined in this study
was enriched with strains that were difficult to type in other labo-
ratories. The clinical significance, if any, of the apparently limited
capsule expression under laboratory conditions is also unknown.
With few exceptions, the PCR-based capsular gene typing
methods accurately identified the strains except for serotypes not
covered by two of the assays. However, in our hands the multiplex
PCR described by Imperi et al. (11) misidentified a few serotype Ib
and IV strains as serotype Ia, and the assay described by Poyart et
al. (14) does not distinguish between serotypes VII and IX. The
latter serotype was identified after publication of the Poyart
method. Thus, the multiplex PCR by Poyart et al. (14) has to be
combined with another PCR in order to distinguish between se-
rotypes VII and IX in strains assigned to serotype VII in the assay.
We suggest to reexamine strains assigned to capsular gene type VII
in this PCR by using primers cpsI-Ia-6-7-F and cpsI-7-R, which
amplify a 179-bp fragment of cpsI in serotype VII strains, together
with primers cpsI-7-9-F and cpsI-9-R, which amplify a 229-bp
fragment of the gene in serotype IX strains as described by Imperi
et al. (11). This combination of two PCR methods provides a
convenient and reliable typing system (Fig. 4).
An inherent disadvantage of capsular gene typing is that the
PCR-based methods do not reveal if the detected cps locus is ex-
pressed as a polysaccharide capsule. Different genetic mechanisms
of capsule loss have been described for S. agalactiae, including
insertion or deletion of DNA fragments in the cps region (13, 18,
19) and variation in the number of nucleotides in homopolymeric
tracts in cps genes (13, 19, 20). The latter is presumably caused by
slipped-strand mispairing events resulting in frameshift muta-
tions, which enable phase variation in capsule expression (21).
Among the 312 strains included in our study, 5 showed evidence
of indels in the cps locus. However, the vast majority of the strains
recorded as noncapsulated by both latex agglutination and flow
cytometry did not show larger indels in the cps region as detected
by a long-range PCR covering the region. Smaller indels of up to a
few hundred nucleotides as described by Kong et al. (13) would
not be revealed by this method due to limitations in resolution of
large DNA fragments by agarose gel electrophoresis.
In conclusion, available serological and gene-based methods
for capsular typing of S. agalactiae all have shortcomings that may
result in lack of or erroneous results. Apart from misidentification
of certain serotypes, the latex agglutination method depends on
experience and is less sensitive than the flow cytometry method.
We suggest that capsular gene typing using the described combi-
nation of existing methods should be included in epidemiological
and surveillance studies of S. agalactiae in order to correctly iden-
tify the full spectrum of serotypes or to confirm serotyping results
obtained by latex agglutination.
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